All News
Filter News
Found 143 articles
-
Gracell Biotechnologies’ CEO Dr. William Cao Named to Prestigious PharmaVoice 100, Honoring Most Inspiring Life Science Leaders
9/19/2023
Gracell Biotechnologies Inc. announced that its Founder, Chairman and Chief Executive Officer William Cao, Ph.D., B.M., has been named to the PharmaVoice 100, a recognition of the most inspiring leaders in the life-sciences industry.
-
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences - September 14, 2023
9/14/2023
Gracell Biotechnologies Inc. today announced that the management team will participate in and attend one-on-one meetings at three upcoming investor conferences.
-
Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 2023 International Myeloma Society Annual Meeting
9/6/2023
Gracell Biotechnologies Inc. today announced that it will present updated, longer-term results from the ongoing investigator-initiated Phase 1 trial in China evaluating FasTCAR-enabled GC012F in transplant-eligible, high-risk patients with newly diagnosed multiple myeloma (NDMM).
-
Gracell Biotechnologies to Participate in Two Upcoming September 2023 Investor Conferences
8/24/2023
Gracell Biotechnologies Inc. announced that the management team will participate in and attend one-on-one meetings at two upcoming investor conferences.
-
Gracell Biotechnologies Reports Second Quarter 2023 Unaudited Financial Results and Provides Corporate Update
8/14/2023
Gracell Biotechnologies Inc. today reported second quarter unaudited financial results for the period ended June 30, 2023, and provided corporate updates.
-
Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors
8/7/2023
Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors.
-
Gracell Biotechnologies to Participate in BTIG Virtual Biotechnology Conference
7/31/2023
Gracell Biotechnologies Inc. today announced that the management team will participate in the BTIG Virtual Biotechnology Conference on August 7 - 8.
-
Gracell Biotechnologies to Report Second Quarter 2023 Financials on Monday, August 14, 2023
7/31/2023
Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”) today announced that it plans to release unaudited financial results for the second quarter ended June 30, 2023 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, August 14, 2023.
-
Gracell Biotechnologies to Participate in Truist Securities Cell Therapy Symposium
6/20/2023
Gracell Biotechnologies Inc. today announced that the management team will participate and host investor meetings in the Truist Securities Cell Therapy Symposium: Symposia-cel on June 27, 2023, in New York.
-
Gracell Biotechnologies Presents Longer-Term Results for FasTCAR-T GC012F in B-Cell Non-Hodgkin’s Lymphoma at EHA2023, Highlighting 100% Overall Response Rate
6/10/2023
Gracell Biotechnologies Inc. presented longer-term follow-up data from a first-in-human study evaluating GC012F, a CD19 and B-cell maturation antigen dual-targeted autologous CAR-T therapeutic candidate, in patients with relapsed/refractory B-cell non-Hodgkin’s Lymphoma as an oralpresentation at the European Hematology Association Congress.
-
Gracell Biotechnologies Presents Updated Data of Deep and Durable Responses for FasTCAR-T GC012F in Relapsed/Refractory Multiple Myeloma at 2023 ASCO Annual Meeting
6/3/2023
Gracell Biotechnologies Inc. presented long-term follow-up data from a multicenter study evaluating GC012F, a B-cell maturation antigen and CD19 dual-targeted autologous CAR-T therapeutic candidate, in RRMM during an oral abstract presentation at the 2023 American Society of Clinical Oncology Annual Meeting.
-
Gracell Biotechnologies to Participate in 2023 Jefferies Healthcare Conference
5/24/2023
Gracell Biotechnologies Inc. announced that the management team will participate in the Jefferies Healthcare Conference on June 8, 2023, in New York, NY.
-
Gracell Biotechnologies Initiates Investigational Study Evaluating GC012F for Treatment of Refractory Systemic Lupus Erythematosus (SLE)
5/15/2023
Gracell Biotechnologies Inc. today announced the initiation of an investigator-initiated trial (IIT) in China of GC012F, the Company's autologous FasTCAR therapeutic candidate dual-targeting B cell maturation antigen (BCMA) and CD19, for the treatment of refractory SLE.
-
Gracell Biotechnologies to Host KOL Webinar on Multiple Myeloma on May 22nd
5/15/2023
Gracell Biotechnologies Inc. today announced that it will host a key opinion leader (KOL) webinar on May 22, 2023 at 9:00 am ET.
-
Gracell Biotechnologies Reports First Quarter 2023 Unaudited Financial Results, and Provides Corporate Update
5/15/2023
Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell” or the “Company”) today reported first quarter unaudited financial results for the period ended March 31, 2023, and provided corporate updates.
-
Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in RRMM and B-NHL and Donor-Derived CAR-T GC007g in B-ALL at EHA2023 Congress
5/11/2023
Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL) today announced that clinical data from three studies in B-NHL, RRMM and B-ALL will be presented at the 2023 European Hematology Association (EHA) Annual Meeting taking place June 8-15 in Frankfurt, Germany, and online.
-
Gracell Biotechnologies to Participate in Two Upcoming May 2023 Investor Conferences
5/10/2023
Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, announced that the management team will participate in and attend one-on-one meetings at two upcoming in-person investor conferences.
-
Gracell Biotechnologies to Report First Quarter 2023 Financials on Monday, May 15, 2023
5/2/2023
Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”) today announced that it plans to release unaudited financial results for the first quarter ended March 31, 2023 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, May 15, 2023.
-
Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F at 2023 ASCO Annual Meeting
4/26/2023
Gracell Biotechnologies Inc. today announced that it will present updated clinical data on GC012F.
-
Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2022
4/25/2023
Gracell Biotechnologies Inc. announced that the company has filed its annual report on Form 20-F for the full year ended December 31, 2022 with the U.S. Securities and Exchange Commission on April 25, 2023.